Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OASIS: Ozurdex vs Avastin for DMO in Aboriginal Australians
NCT04619303Phase 4Completed
- Sponsor
- Lions Eye Institute
- Start
- Feb 2017
- Primary completion
- Feb 2020
- Modality
- Implantable Devices, Implantable Hydrogels, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of ozurdex in diabetic macular edema (DME) (2 arms), sponsored by Lions Eye Institute. Primary endpoint: Difference in best corrected visual acuity change between treatment arms at 12 months. Started Feb 2017; status: completed.
02
Drugs
ozurdex
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT04619303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04619303.